Why Attend
CAR-T cell therapy has shown unparalleled success in haematological malignancies, paving the way for the field of immuno-oncology. In 2017 two therapies achieved FDA approval in the USA, and following recent approval by the EMA, it is a landmark time for the industry.
Despite the huge successes there are still a number of hurdles to overcome before CAR-T can be effective in mainstream oncology beyond haematological malignancies. The European CAR-T Congress’ mission is to address the opportunities and challenges that presently face the CAR-T field, to maximise the potential of this ground-breaking therapy.
Sessions include:
- Solid tumour targeting: overcoming the tumour microenvironment
- Multi-specific & dual targeting CARs
- Process development, scalability & automation
- Allogeneic vs Autologous: the potential of off-the-shelf therapies
- Patient access, implementation & regulatory challenges
- Advances in gene engineering
- Safety and toxicity
2018 IMAGE GALLERY
TESTIMONIALS
WHO WILL BE THERE
Network with industry experts from:
- Big pharma and biotech
- Cell Therapy Academics and clinicians
- Process standardisation - technology/services
- Logistics companies - cell storage/transport
- Service providers - CRO’s, Consultants, Government
Past attendees include:
The Agenda
Simply fill in this form and we'll send you a PDF version of the agenda immediately. We need some information to know where to send the file and how to address our email to you.
Check out the highlights from the CAR-T Congress USA earlier this year:
Download agenda
The Speakers
Michael Kalos
Michael Kalos is a graduate of the University of Minnesota Medical School, where he received his PhD from the department of Microbiology with an emphasis in Genetics. He completed postdoctoral fellowships at the Fred Hutchinson Cancer Research Center where he played an early role in the development of genetic approaches to redirect lymphocyte specificity.
In 1997 Dr. Kalos joined Corixa Corporation, where he engaged in the pre-clinical immunological evaluation of novel cancer vaccines for prostate and lung cancer.
In 2004 Dr. Kalos was recruited to City of Hope where he established a GLP-level laboratory focused on the development of biomarker strategies to evaluate T cell immunotherapies.
In 2008 Dr Kalos was recruited to the University of Pennsylvania School of Medicine where he established the Translational and Correlative Studies Laboratory, focused on development and implementation of an integrated biomarker infrastructure as part of the institution's T cell immunotherapy program. Data from his laboratory played an instrumental role in the clinical evaluation and development of the CTL019 program, and has led to a series of high-impact and field-leading publications.
In October 2013 Dr Kalos joined Eli Lilly and company as Chief Scientific Officer for Cancer Immunobiology. At Eli Lilly Dr. Kalos was responsible for establishing and developing a robust and product focused immunotherapy strategy and program.
In March of 2018 Dr. Kalos joined Janssen as Vice President, Immuno-oncology and Oncology Cellular Therapies, where is responsible for developing and leading an integrated Immunotherapy program focused on next-generation and transformative immune therapies.
Dr. Kalos is an internationally recognized expert in T cell immunotherapy.
Dr John Maher
Kip Cross
Peggy Sotiropoulou
Dan Ollendorf
Dr. med. Detlev Parow, MBA
Dr David Sourdive, PhD
David Sourdive, Ph.D., is a co-founder of Cellectis and joined the Board of Directors in 2000. Dr. Sourdive holds the position of Executive Vice President, Technical Operations, with the mission to develop the Company’s industrial and technological basis as well as to deploy its operations in the pharmaceutical arena. Dr. Sourdive combines a strong scientific expertise with experience in managing industrial programs bringing innovative technologies to industrial fruition. He served as Executive Vice President, Corporate Development, from 2008 to 2016. In addition to his role at Cellectis, Dr. Sourdive has also served on the board of directors of the Mediterranean Institute for Life Sciences. David Sourdive graduated from École Polytechnique, received his Ph.D. in molecular virology at Institut Pasteur and completed a research fellowship in the Emory University Department of Microbiology and Immunology. His management training is from the HEC (Challenge +) and his decade-long experience in industrial program management was acquired at the French Department of Defense (DGA) prior to Cellectis’ inception.
Fiona Thistlethwaite
John Bridgeman
Michaela Sharpe, PhD
Michaela Sharpe is the Head of Nonclinical Safety and Immunotherapy Strategy at the Cell and Gene Therapy Catapult. Michaela has over fifteen years’ experience in the Pharmaceutical Industry both in the biotechnology sector and large pharma where she has specialised in the nonclinical development of cell based therapies and therapeutic vaccines. She was Head of the Stem Cell Safety Group at Pfizer and prior to joining the Catapult she ran her own consultancy business. Michaela oversees Immunotherapy Strategy for the Catapult as well as leading a team with significant expertise in the design of non-clinical safety programmes and the development of specialist clinical assays. She has implemented nonclinical development programmes for pluripotent stem cell therapies, somatic cell therapies, immune therapies, genetically modified cell therapies and tissue engineered products.
Thierry Wurch
Alasdair Rankin
Alasdair Rankin is Director of Research and Patient Experience at the blood cancer research charity Bloodwise. In addition to research, his responsibilities include Bloodwise’s policy and campaigning work, and its information and support services for people affected by blood cancer. Previously he was Director of Research at Diabetes UK from 2012 to 2015 where he developed the organisations current research strategy, including leading the establishment of diabetes Clinical Studies Groups and broadening engagement of people living with diabetes in research. He began working for research funders at Cancer Research UK, where he held various roles including leading the research funding operations team and establishing and leading the research strategy team, contributing to the development and implementation of Cancer Research UK’s 2011-15 research strategy. Alasdair is an elected Trustee of the National Cancer Research Institute.
Luis Álvarez-Vallina
Luis Álvarez-Vallina attended Medical School at Oviedo University and completed a residency in Immunology at the Clínica Puerta de Hierro (Madrid). Luis earned a PhD in Immunology from the Autónoma University of Madrid and spent four years at the MRC Centre for Protein Engineering (Cambridge, UK). His work contributed to the first generation of CARs with costimulatory domains. Currently, he is Associate Professor at Aarhus University (Denmark) where he leads the Immunotherapy and Cell Engineering group. He is also heading the Cancer Immunotherapy Unit at Hospital Universitario 12 de Octubre, and Director Immunology Chair Merck- Francisco de Vitoria University (Spain). His experience includes generation of multispecific antibodies, and the development of cancer immunotherapy strategies based on the adoptive transfer of genetically engineered cells secreting bispecific antibodies.
Michael Hudecek
Dr Zoltan Ivics
Dr Sarah Snykers
Sarah has over 10 years of experience in cell therapy, biomedical research and development.
She is a pharmacist from education and has a PhD in pharmaceutical and biomedical sciences, specialised in stem cell biology. In 2010, she joined Promethera BioSciences, a biopharmaceutical company dedicated to the development of cell therapy products based on allogeneic adult stem cell technology to treat liver diseases. She headed the R&D, QC and Preclinical Departments. In 2015, she joined Celyad, a biopharmaceutical company, specialised in autologous and allogeneic cell therapy. Celyad’s core business lies in the field of immune-oncology, and more specifically the development of NK-receptor based CAR T therapies. Sarah initially led the immune-oncology program at R&D level, focused on technology transfer, product characterization and optimization. Since 2016, she heads the QC Department.
Anna Prokůpková
Dr Ignacio Anegon
Dr Gemma Owens
Gemma Owens is a clinical research fellow and registrar in obstetrics and gynaecology with a specialist interest in gynaecological cancers. She attended Medical School at Queen’s University (Belfast), and completed an Academic Clinical Fellowship at St Mary’s Hospital, Manchester. She has recently completed a PhD at the University of Manchester, where she worked with Professor Robert Hawkins, Professor Richard Edmondson and Dr David Gilham. Her PhD focused on adoptive immunotherapy strategies for epithelial ovarian cancer, working on both TIL and CAR-T cell approaches. In collaboration with Oxford Biomedica, Gemma has demonstrated that 5T4 is an attractive target for CAR-T cell therapy in ovarian cancer.
Nia Emami
Dr. Yannick Bulliard
Dr. Paul Lammers
Merethe Frosig
Wolfgang Schamel
Poster submission - deadline 14.12.2018
Looking to showcase your recent work to the CAR-T community?
Our dedicated poster session is the perfect way to get your research noticed and further involve yourself in the congress. In order to present a poster at the forum you need to be registered as a delegate. Please note that there is limited space available and poster space is assigned on a first come first served basis (subject to checks and successful registration).
At the Congress, your presentation will be displayed in a dedicated poster area. The poster presentation session will take place at the afternoon networking break on day one.
Submit your poster abstract here.
Poster abstract submission deadline is on 14th December 2018.
Abstracts received after this time may not be accepted so please submit your abstract as soon as possible!
Expertise Partner
Miltenyi Biotec
Website: http://www.miltenyibiotec.com
At Miltenyi Biotec, we are committed to enabling the delivery of new cell and gene therapy (CGT) treatment options to patients with unmet medical needs. We develop tailored cell processing protocols for our GMP-compliant cell processing platform, the CliniMACS Prodigy®, to enable fully closed and automated manufacturing of complex CGT products. In addition, we offer contract development and GMP manufacturing of CGT products as well as design, development, and production of tailored GMP lentiviral vectors
Registration Host
Servier
Website: http://www.servier.com
Servier is an international and independent pharmaceutical company governed by a non-profit foundation, with headquarters in France. Since opening our first laboratory in 1954, we have been committed to therapeutic progress to serve patient needs with the help of healthcare professionals. We strive to provide future generations with a world where quality healthcare is available and accessible to all.
Operating in 149 countries, we have 21,700 collaborators employed worldwide and a turnover of 4.152 billion euros in 2017. Entirely independent, we are able to reinvest 25% of our total revenue (excluding generics) into Research and Development, and all profits are used for further development.
Corporate growth at Servier is driven by our continuous pursuit of innovation in five areas of excellence: cardiovascular and immune-inflammatory diseases, neuropsychiatric disorders, cancer and diabetes. We are a leading force in cardiology and oncology has become a top priority in recent years; we also manufacture high-quality generic drugs.
All our employees are driven by shared values and guided by a common vision. Together we share the passion of entrepreneurship and we are committed to therapeutic progress to serve patient needs.
Event Partner
Pharmametrics
Website: http://www.pharmametrics.com/
Founded in 1990 and located in the university town of Freiburg in Germany, Pharmametrics is a healthcare consulting company focusing on scientific evidence-based research in epidemiology, health economics & outcomes research (HEOR), health technology assessments (HTA) and market access. Pharmametrics GmbH is privately owned and has been offering a rich array of research, consulting and advisory services for the last 25 years.
With a network of excellent expertise worldwide Pharmametrics GmbH is committed to producing high quality, scientifically rigorous information, databases, portals and software solutions to support our clients’ strategic decision making. This commitment is fulfilled through working closely with clients during all phases of a project to ensure that the deliverables achieve the objective to support their strategic decision making.
ChemoMetec
Website: http://chemometec.com
ChemoMetec is a Danish founded company, which specializes in the development, manufacturing and sales of high-quality automated Cell Counters, Advanced Cell Analyzers and Image Cytometers to help streamline research, process development, and manufacturing processes for maximum efficiency. Our instruments are based on a patented, unique technology platform that ensures high quality analysis of results and consistency between samples. The instruments are known for their robustness and high precision, as well as advanced analysis capabilities with a user friendly interface.
Our technology is rapidly becoming the gold standard for cell count and viability in the field of CAR-T and T-cell therapy. The reason for this is that our cell counters deliver the highest level of precision amongst all counting methods, as well as being 21CFR part 11 ready. Part of the secret to this precision is the Via-Cassette TM which eliminates user error due to sample/reagent mixing and pipetting. In addition, every cassette is individually volume calibrated to ensure accurate calculation of cell concentration. Also, every instrument is calibrated to a master instrument to ensure that you get the most precise count possible. This eliminates inter-instrument variation between your CAR-T research team, manufacturing, and QC monitoring of the final product.
nanoString
Website: https://www.nanostring.com/
NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter® Analysis System, which has been employed in basic and translational research and cited in 1,000+ peer review publications, has also now been applied to diagnostic use with the nCounter Dx Analysis System. The company is committed to offering tools that enable scientists and clinicians to translate today’s leading genomic research into clinically actionable tests that improve patient care. Gene expression panels for immune- oncology, autoimmunity, CAR-T and other applications are ready off the shelf tools offered to the Nanostring customers.
PeproTech
Website: http://www.peprotech.com
Established in 1988 by a group of scientists, PeproTech is a privately owned biotechnology company focusing on the development and manufacture of high quality cytokine products for the life-science and cell therapy markets. Over the past 30 years the company has grown into a global enterprise with state-of-the-art manufacturing facilities in the US, and offices around the world.
With over 2,000 products PeproTech has developed and refined innovative protocols to ensure quality, reliability and consistency.
Our mission is to provide the highest quality products to support the needs of today’s scientists and researchers.
Please contact: 020 7610 3062 or [email protected]
Biocair
Website: https://www.biocair.com/
Biocair is one of the world’s leading bioscience couriers with over 30 years of expertise in the pharmaceutical, biotechnology and life science sectors. Wholly owned by the DPD group, Biocair has built up a unique, client-centric approach by employing scientists in front-line logistics positions and assembling a team of best-in-class industry experts in quality, cold chain and regulatory compliance amongst others. Biocair focuses on providing the most comprehensive service options available whilst delivering flexible, tailored, cost-effective logistics solutions to all its clients.
Founded in Cambridge (UK), Biocair’s global reach now extends across continental Europe, US, Africa and Asia. In each location across the world Biocair’s staff have a solid understanding of the nature of the materials we transport - this enables them to understand what our clients have been through to produce their materials and how valuable and delicate they can be.
Cellbox Solutions
Website: https://cellbox-solutions.com
Cellbox Solutions GmbH is a young technology company focusing on innovative logistic solutions for the global BioMedTech industry. The company, founded in 2016, is a spin-off from the Fraunhofer Research Institution for Marine Biotechnology and Cell Technology in Lübeck, Germany. Our portable CO2 incubator, the Cellbox, provides a safe environment for the transport of living cells and biological structures under laboratory conditions. Equipped with a range of advanced sensors, the Cellbox accurately regulates the temperature and CO2, while logging the internal conditions during transport. Whether the intended transport is by air, sea, road or rail, the Cellbox is the perfect solution for secure and reliable shipping.
Terumo BCT
Website: http://www.terumobct.com
Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular technologies, believes in the potential of blood and cells to do even more for patients than they do today. Terumo BCT’s Cell Therapy Technologies business enables researchers, developers and manufacturers to create next-generation cell and gene therapies. We do this through flexible, automated solutions that help meet your evolving needs for reproducibility, quality and scale through the phases of development, from translational research to current good manufacturing practice (cGMP) for commercial manufacturing. One example, the Quantum® Cell Expansion System automates and optimizes cell culture to meet the needs of a variety of cell types in a consistent, controlled and functionally closed environment. We are also looking further downstream in the process to provide innovative solutions, like the FINIA® Fill and Finish System, to support your needs into the future.
Media Partners
BioInformant
Website: https://www.bioinformant.com
As the first and only market research firm to specialize in the stem cell industry, BioInformant research has been cited by the Wall Street Journal, Xconomy, and Vogue Magazine. Today, BioInformant.com is the world's largest publisher of cell therapy industry news, serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs.
Gene Therapy Net
Website: http://www.genetherapynet.com
Gene Therapy Net is the information resource for basic and clinical research in gene therapy, and the site serves as a network in the exchange of gene therapy information and breaking news items. Visitors can keep track of the latest scientific papers, conference announcements, gene therapy jobs, regulations and guidelines.
Cell Therapy News
Website: http://www.celltherapynews.com
Connexon Creative’s mission is to accelerate science and facilitate science communication by providing tools that enhance the way scientific and medical professionals keep up with recent findings, science news and exciting advances in specific areas of immunology and cell biology research.
pharmaphorum
Website: http://pharmaphorum.com
pharmaphorum is a content and communications company offering a unique hybrid of publisher and agency working in pharma and healthcare.
pharmaphorum.com is our own independent flagship publication. It serves over 3 million unique users annually and its news and information is widely recognised as a leading source of thought leadership and strategic content for pharmaceutical professionals all over the world.
Our innovative digital magazine Deep Dive provides cutting edge insight on pharma industry trends to an audience of 100K per issue.
Human Gene Therapy
Website: http://www.liebertpub.com/hgt
Human Gene Therapy is the premier, multidisciplinary journal covering all aspects of gene therapy. The Journal publishes in-depth coverage of DNA, RNA, and cell therapies by delivering the latest breakthroughs in research and technologies. Human Gene Therapy provides a central forum for scientific and clinical information, including ethical, legal, regulatory, social, and commercial issues, which enables the advancement and progress of therapeutic procedures leading to improved patient outcomes, and ultimately, to curing diseases.
The Journal is divided into three parts. Human Gene Therapy, the flagship, is published 12 times per year. HGT Methods, a bimonthly journal, focuses on the applications of gene therapy to product testing and development. HGT Clinical Development, a quarterly journal, serves as a venue for publishing data relevant to the regulatory review and commercial development of cell and gene therapy products.
Become a Sponsor
Kisaco Research provides the much needed platform on which industry executives can network, connect and learn from each other as well as meet potential industry partners.
Far from the typical ‘meet-and-greet’ exhibition experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand, rather than just a name on an exhibition list.
With our extensive marketing experience and strategy, your partnership with Kisaco Research will grant you a sponsorship package that is an extension and enhancement of your current marketing and branding efforts. We value your ROI and will work with you directly on your specific goals and targets – that’s why we take special care in finding the most relevant end-users to attend, so that your financial and resource investment is smartly allocated.
Find out more by calling us at +44 (0)20 3696 2920 or email us at [email protected].
Sending Your Team? Group Discounts Available!
Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates
Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off
If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920
Book a Team to Save More!
PLEASE NOTE: Team Discounts are only available for Industry Pricing
Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off
Payment Terms for Combined CAR-T Congress Europe:
- Please note that a £49 processing fee will apply to any invoices requested.
- All Prices are in GBP and are exclusive of VAT @ 20%
- All Early Bird discount prices, including Group Discounts, must be paid in full by deadlines provided above.
- No discounts or offers can be combined with any other offer.
- Please view our Cancellation Policy.
- QUESTIONS? Please email [email protected].
Pass Features:
- 2 Day conference pass
- Networking Sessions
- Lunch and Refreshments
Complimentary Articles and Content
Venue
Millennium Gloucester Hotel, 4-18 Harrington Gardens, Kensington, London, SW7 4LH
Europe's second CAR-T Congress will be taking place in Millenium Gloucester Hotel, London.
Situated in stylish , the 4-star Millennium Gloucester Hotel London is 100 yards from Gloucester Road Tube Station. It offers elegant air-conditioned rooms, a wide array of on-site dining options and a fitness room.
Bedroom rate: £140.00 + vat including breakfast (single occupancy)
Book now:
T: + 44 (0) 207 331 6195 reseverations direct line or main hotel on +44 (0) 207 373 6030
Book by 29 December 2018 and always quote KISA290119 to benefit from this rate.
Accessibility:
We are committed to making our event accessible for everyone. If you are traveling for the event, Cloud of Goods provides mobility scooter rentals, wheelchair rentals, and other mobility solutions. They will deliver directly to you at the event, your hotel, the airport, or any other place of your choosing. Event attendees will receive a 20% discount when they use the code: RENTGEAR032
About Kisaco Research
Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.
Meet industry peers that will help build a career-changing network for life.
Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.
Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.
Invest both in your company growth and your own personal development by signing up to one of our events and get started.